Aryx shares slammed by disapointing trial results for blood thinner(0)
Shares of Aryx Therapeutics, the Fremont biopharmaceutical, got bombed Wednesday following news released late the day before that its latest clinical trial of tecafarin, its novel blood-clot treatment, failed to achieve better results than wafarin, a blood-thinner sold by Bristol- Myers Squibb that was developed six decades ago.
Ayrx’s stock ended the trading day falling Read the rest of this entry »
Subscribe via RSS all feeds